Comparative Pharmacology
Head-to-head clinical analysis: COXANTO versus LODINE XL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COXANTO versus LODINE XL.
COXANTO vs LODINE XL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of soluble epoxide hydrolase (sEH), increasing levels of epoxyeicosatrienoic acids (EETs), which have vasodilatory, anti-inflammatory, and antifibrotic effects.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis leading to anti-inflammatory, analgesic, and antipyretic effects.
1 g intravenous every 6 hours.
400 mg or 600 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours (prolonged to 24-30 hours in moderate-to-severe renal impairment, requiring dose adjustment)
Terminal elimination half-life is approximately 6-7 hours. Steady-state is achieved within 2 days.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Renal excretion of metabolites accounts for approximately 70% of a dose; fecal excretion accounts for about 20%.
Category C
Category C
NSAID
NSAID